Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06865651 · ClinicalTrials.gov registry record · Phase 2
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
A Phase 2 study of Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU), sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 17
- Study locations
NCT06865651 is a Phase 2 study of Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU) that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 44 participants. The trial reports 17 study locations across 6 states.
The verdict
NCT06865651, a Phase 2 study of Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU), is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to explore the effect and Mechanism of Action (MoA) of remibrutinib (LOU064) vs. placebo on clinical outcomes in participants with Chronic Urticaria (CU), including both Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CINDU).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Remibrutinib
Study Locations (17)
Other
- Novartis Investigative Site - Grenoble
- Novartis Investigative Site - Montpellier
- Novartis Investigative Site - Paris
- Novartis Investigative Site - Pierre-Bénite
- Novartis Investigative Site - Berlin
- Novartis Investigative Site - Mainz
- Novartis Investigative Site - Tübingen
- Novartis Investigative Site - Poznan
- Novartis Investigative Site - Rzeszów
- Novartis Investigative Site - Warsaw
- Novartis Investigative Site - Alicante
- Novartis Investigative Site - Madrid
Florida
- Ziaderm Research LLC - North Miami Beach
Illinois
- Endeavor Health - Glenview
Saxony
- Novartis Investigative Site - Dresden
Catalonia
- Novartis Investigative Site - Barcelona
Navarre
- Novartis Investigative Site - Pamplona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2025-05-22 |
| Est. Completion | 2027-10-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06865651
The ClinicalTrials.gov registry entry for NCT06865651 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06865651 reports 17 study locations spanning 6 distinct geographic areas - top geographies include Other, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06865651 about?
NCT06865651 is a clinical study titled "Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria". The purpose of this study is to explore the effect and Mechanism of Action (MoA) of remibrutinib (LOU064) vs. placebo on clinical outcomes in participants with Chronic Urticaria (CU), including both Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CINDU).
What is the current status of trial NCT06865651?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2025-05-22. Estimated completion is 2027-10-07.
What conditions does trial NCT06865651 study?
This clinical trial studies the following conditions: Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU).
What interventions are being tested in trial NCT06865651?
The interventions under investigation include: Placebo (DRUG), Remibrutinib (DRUG).
Who is sponsoring clinical trial NCT06865651?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06865651 being conducted?
This trial has 17 study locations across Florida, Illinois, Saxony, Catalonia, Navarre. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.